Drugs / JSI-1187
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06239623 | Apr 2022 → Sep 2024 | melanoma, non-small cell lung carcinoma | JS InnoPharm, LLC | Unknown | No outcome recorded |
| Phase 1 | NCT04418167 | Jun 2020 → Dec 2025 | cancer | JS InnoPharm, LLC | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JSI-1187 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06239623 ↗ |
| Action | Inhibit | “ERK1/2 Inhibitor JSI-1187” NCT04418167 ↗ |
| Route | Oral | “JSI-1187 capsules for oral administration” NCT04418167 ↗ |